Olpinat (Olanzapine)

Olpinat is an atypical antipsychotic that acts on dopamine and serotonin pathways to treat serious mental health conditions.

• Schizophrenia: helps reduce hallucinations, delusions and thought disorder.
• Bipolar I disorder (manic episodes): stabilises mood and diminishes manic symptoms.
• Acute psychotic episodes: provides rapid symptom control in emergency settings.
• Maintenance therapy for schizophrenia: supports long‑term relapse prevention.
• Adjunctive treatment in major depressive disorder with psychotic features: augments antidepressant response.
• Off‑label use for anxiety disorders: sometimes considered when other agents are ineffective.

• Olanzapine exerts its antipsychotic effect by antagonising dopamine D2 receptors and serotonin 5‑HT2A receptors, with additional activity at 5‑HT2C, muscarinic, histamine H1 and α‑adrenergic receptors. This broad receptor profile reduces dopaminergic transmission in mesolimbic pathways while modulating serotonergic activity, leading to improvement in psychotic and mood symptoms.

Olpinat may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects

• Weight gain: increased appetite and caloric intake.
• Sedation: drowsiness or feeling unusually sleepy.
• Metabolic changes: elevated blood glucose and lipid levels.
• Dry mouth: reduced salivation.
• Constipation: slowed gastrointestinal motility.
• Orthostatic hypotension: light‑headedness on standing.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability.
• Tardive dyskinesia: involuntary, repetitive movements, often of the face.
• Severe hyperglycaemia: diabetic ketoacidosis or hyperosmolar state.
• Agranulocytosis: dangerously low white‑blood cell count.
• Myocardial infarction or stroke: increased cardiovascular risk.
• Seizures: especially in patients with a history of epilepsy.

Before initiating Olpinat, clinicians should evaluate patient history and monitor relevant parameters.

• Baseline metabolic assessment: record weight, fasting glucose and lipid profile.
• Monitor for extrapyramidal symptoms: watch for involuntary movements.
• Assess cardiovascular risk: check blood pressure and lipid levels regularly.
• Review hepatic and renal function: adjust if significant impairment exists.
• Pregnancy and lactation counseling: discuss potential risks and benefits.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Olpinat can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP1A2 inhibitors (e.g., fluoxetine, ciprofloxacin): increase olanzapine plasma levels.
• CNS depressants (benzodiazepines, opioids): enhance sedation and respiratory depression.
• Anticholinergic agents: may worsen dry mouth and constipation.

Moderate Interactions (Monitor Closely):\n- Smoking: induces CYP1A2, potentially lowering olanzapine concentrations.

• Antihypertensive drugs: additive hypotensive effect.
• Lithium: combined use may increase risk of neurotoxicity.
• Diabetes medications: olanzapine‑induced hyperglycaemia may require dose adjustments.
• QT‑prolonging agents: monitor ECG for arrhythmia risk.